Liquid biopsy startup Thrive Earlier Detection Corp. has raised $257 million in a series B round led by Casdin Capital and Section 32. The funds will be used to finalize the design of its first product, Cancerseek, conduct a trial to support U.S. FDA approval and prepare for commercialization.

HONG KONG – Daejeon, South Korea-based biotechnology company G2GBIO Inc. has raised ₩11.4 billion (US$9.53 million) from a series B financing round, with the funds to be used on clinical trials for a sustained-release Alzheimer’s treatment as well as nonclinical trials for diabetes and sustained-release postoperative pain treatments.

Indigo Diabetes NV is working to develop a next-generation continuous glucose monitor (CGM) that would be much simpler and easier to use routinely, potentially making it more useful for a much larger population. It has just raised a €38 million ($44.5 million) series B financing to support that effort.

HONG KONG – Daejeon, South Korea-based biotechnology company G2GBIO Inc. has raised ₩11.4 billion (US$9.53 million) from a series B financing round, with the funds to be used on clinical trials for a sustained-release Alzheimer’s treatment as well as nonclinical trials for diabetes and sustained-release postoperative pain treatments.

Bone fracture repair startup Curvafix Inc. has secured $10.75 million in a series B round led by Sectoral Asset Management with participation from existing investors, including Delta Dental Washington Seed Fund, as well as board members. The company will use the proceeds to complete the RESTORE clinical trial of its U.S. FDA-cleared Curvafix intramedullar rodscrew and to scale up for commercial launch later this year or in 2021.

Glympse Bio has closed an oversubscribed $46.7 million series B financing, with an eye toward boosting its novel biosensor platform in fibrotic diseases, including nonalcoholic steatohepatitis (NASH), oncology and infectious diseases.

LONDON – Varmx BV is poised to demonstrate its modified recombinant factor X acts a universal antidote to reverse the effects of direct oral anticoagulants in patients suffering severe spontaneous bleeding or needing emergency surgery, after closing a €32 million (US$36.1 million) series B round.

Velosbio Inc., a San Diego-based company developing cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), has raised $137 million in series B financing to support development of its lead antibody-drug conjugate (ADC), VLS-101, and continued expansion of its pipeline.

Startup Brightinsight Inc. is working to make the infrastructure behind digital health easily accessible to pharma and med-tech companies. To aid it on this path, the San Jose, Calif.-based company has raised a $40 million series B round to expand its capabilities and global reach.

BEIJING – CAR T therapy developer JW Therapeutics (Shanghai) Co. Ltd. raised another $100 million this week after securing $90 million in series A round in 2018. The funds will continue to go toward its lead program, JWCAR-029, a CAR T-cell product targeting CD19 that is now in a phase II study.